Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

NEXT STORY
The Fc protein and glyco-engineered antibodies market is projected to grow at a CAGR of over 30% during 2021-2030, claims Roots Analysis
PREV STORY
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

author_avatar
NASDAQ Market News

Ehave, Inc. To Acquire Mdlink The Largest Telemedicine Platform in The CARICOM Countries And To Launch Mdlink Mental Therapy along with Psychedelic Treatments To Address Mental Health

author_avatar
NASDAQ Market News

Agritek Holdings, Inc. Announces Focus on Production of CBG Enriched Hemp Material and Retail Products as New Research Uncovers Hidden Antibiotic Potential to Fight Viral Symptoms in Humans

author_avatar
NASDAQ Market News